CROs/Service Providers

Encorium Group Scores $1.7 million Phase II Contract

Monday, July 16, 2007

Wayne, Pa.-based CRO Encorium Group has inked a $1.7 million deal to manage a phase II trial in major depressive disorder for an unnamed biotech company based in Japan. Encorium will provide site management and monitoring, data management, biostatistical support and medical writing for the study. Encorium stated it intends to pursue further opportunities in the Japanese market and has made that market one of its key long-term business strategies. Recently, the company signed a $3.8 million contract to conduct phase IIb clinical trials with a new antiviral agent for the treatment of shingles (herpes zoster).

[Read More]

Clinquest Group Acquires Stake in Enceladus Pharmaceuticals

Monday, July 9, 2007

Amsterdam-based CRO Clinquest Group has acquired a stake in Enceladus Pharmaceuticals, the Netherlands-based developer of the inflammatory disorder treatment Nanocort—the product is in phase II trials. Clinquest also gathered a group of additional investment groups to back Enceladus as it brings more products to market.

[Read More]

Criterium Opens Offices in Russia, Israel

Tuesday, July 3, 2007

Saratoga Springs, N.Y.-based contract research organization (CRO) Criterium has opened two new offices in St. Petersburg, Russia, and Yavne, Israel. Criterium made its announcement recently at the 43rd Drug Information Asociation (DIA) annual meeting in Atlanta, Georgia.

[Read More]

Trio Offers Webinar Training Series on Adaptive Trials

Wednesday, June 27, 2007

Maryland-based CRO United BioSource Corporation (UBC), in conjunction with eClinical firm Medidata Solutions, and the adaptive trials tools and modeling company Tessella, have joined together to educate the industry on the use of adaptive clinical trials in drug development. The companies are producing a series of free webinars—six in total—that will feature expertise from industry professionals and regulatory authorities on how to overcome some of the challenges of these studies.

[Read More]